FORBIDDEN CURES
Claim 13 FREE reports containing forbidden natural cures the medical establishment doesn't want you to havemore info...
NEW HOPE FOR PAIN SUFFERERS!
Discover the very latest groundbreaking advances in pain relief . . .more info...
Pharmaceutical industry: More shocking tactics used by drug giants
Yet more underhand tactics have been employed by the pharmaceutical industry.
You may remember a recent e-alert 'The arthritis drugs that can increase heart attack risk' (03/03/05) I sent you about the current situation in the US regarding a class of pain-killing drugs called COX-2 inhibitors.
The US Food and Drug Administration (FDA) formed an advisory panel which voted to keep these potentially harmful drugs which include Vioxx, Celebrex and Bextra on the US market. Recent research has shown that the use of these drugs sharply increases the risk of heart attacks.
So, WAS the panel fixed?
That question was posed by a recent CBS online report that took a closer look at the 'expert' FDA advisory panel.
Reading the evidence below it would certainly seem that way.
Examining the examiners
In the previous e-alert I sent you we looked at some of the 'finer' points of the US advisory panel's decision. And now we're getting a revealing look at the panel itself.
According to CBS News, 10 of the 32 panellists had financial ties to Pfizer (the maker of Celebrex and Bextra), Merck (the maker of Vioxx) or Novartis, a company that has submitted an application with the FDA for yet another brand in this class of drugs. The Novartis drug is called Prexige, and how that might be pronounced is anybody's guess. (With any luck we'll never find out.)
CBS reports that the 10 'connected' panellists voted 9 to 1 in support of keeping Bextra on the US market. They also voted 9 to 1 to allow sales of Vioxx even though Merck pulled Vioxx off the US market last year after a study showed that heart attack and stroke risk were doubled when taking the drug.
If these 10 'experts' had not been drafted for the panel, neither Bextra nor Vioxx would have received enough votes to get the panel's thumbs up.
Celebrex did better in the voting because, despite studies that have shown it to also increase heart attack risk in higher doses, the perception is that it's not as dangerous as Vioxx or Bextra. Nevertheless, sales of Celebrex have dipped. No surprise there really. But executives at Pfizer and Merck can't be too upset. After all, the panel didn't vote to pull the drugs altogether. And in the days since the lenient decision from the panel was announced, stock prices for Pfizer and Merck have been climbing.
So everybody wins! Well, not everybody. The consumers of these drugs are surely wondering where the truth is among all the mixed signals.
Denial, rejection & heat
Dr Curt Furberg was one of the panel members who did not have any drug company ties. He told the New York Times that during deliberations, he didn't feel comfortable with 'the Pfizer-friendly undertone' of the meetings. By Dr. Furberg's estimate, as many as 50 people each day may die as a result of taking these drugs. He posed this question to the Times, 'Who is speaking for them?'
The answer: David Graham, the associate science director of the FDA's Office of Drug Safety.
In a controversial testimony before the US Congress last year, Mr. Graham named several popular drugs that should be avoided because of safety concerns. Bextra was one of those drugs. Previously, Mr. Graham also presented evidence that Vioxx increased stroke and heart attack risk.
But Mr. Graham says he encountered considerable resistance from FDA officials who didn't want him to publicise his findings. According to an Associated Press report, he told the Congressional committee that when safety questions arise regarding drugs already approved by the FDA, the agency responds with 'denial, rejection and heat.'
And he could add to that list: fixed panels.
Like I mentioned in the e-alert I sent you on the 3rd of March, let's hope the UK doesn't follow suit.
Click here to send to a friendShare thisPrinter friendly version
